ORGO (Organogenesis Holdings) Stock Based Compensation: $13.6 Mil (TTM As of Mar. 2026)


ORGO Organogenesis Holdings Inc ORGO
67 GF Score
Price $2.47
GF Value $3.08
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Organogenesis Holdings Stock Based Compensation?

Organogenesis Holdings ORGO -0.80% 67 Stock Based Compensation is $13.6 Mil as of Mar. 2026. GuruFocus rates ORGO with a GF Score™ of 67/100 and a GF Value™ of $3.08 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Organogenesis Holdings's Stock Based Compensation for the three months ended in Mar. 2026 was $3.6 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $13.6 Mil.

Organogenesis Holdings Stock Based Compensation Related Terms

Organogenesis Holdings Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Organogenesis Holdings's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organogenesis Holdings Stock Based Compensation Chart

Organogenesis Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.86 6.55 9.00 10.58 13.30

Organogenesis Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.37 2.54 3.07 4.32 3.64
ORGO
67GF Score
Organogenesis Holdings Inc ORGO
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Organogenesis Holdings Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.6 Mil.

What does a Stock Based Compensation of $13.6 Mil mean?
Organogenesis Holdings (ORGO) has a Stock Based Compensation of $13.6 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Organogenesis Holdings and its competitors.
Is Organogenesis Holdings' Stock Based Compensation too high?
Organogenesis Holdings' current Stock Based Compensation is $13.6 Mil. Overall, Organogenesis Holdings has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' Stock Based Compensation compare to TKNO and AKBA?
Organogenesis Holdings' Stock Based Compensation of $13.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Organogenesis Holdings and its competitors. Organogenesis Holdings's current Stock Based Compensation is $13.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (ORGO) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.08, compared to a current price of $2.47 — trading 19.8% below its estimated fair value. The current Stock Based Compensation is $13.6 Mil. Organogenesis Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Organogenesis Holdings (ORGO), the current Stock Based Compensation is $13.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organogenesis Holdings (ORGO) Overvalued in 2026?

Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued. The current stock price of $2.47 is trading 19.8% below its estimated GF Value™ of $3.08. GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.

Key valuation signals for ORGO:

  • Stock Based Compensation: $13.6 Mil
  • GF Value™: $3.08 vs. price of $2.47 (19.8% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the ORGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Organogenesis Holdings Business Description

Other Exchanges 2PQ:Germany
Address 85 Dan Road, Canton, MA, USA, 02021
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
67GF Score

Get the complete analysis for ORGO

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.47
Price
$3.08
GF Value